S. Prakash

Micropharma (Canada)

Health Outcomes Studied

• Reduced Low-Density Lipoprotein Level
• Reduced Total Cholesterol Levels

Papers (8)

• 2015
  Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 3024210.1080/19490976.2015.1005474
• 2013
  Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial10.1517/14712598.2013.833601
• 2013
  Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial.10.1210/jc.2012-4262
• 2012
  In vitro and in vivo characterization and strain safety of Lactobacillus reuteri NCIMB 30253 for probiotic applications.10.1139/w2012-050
• 2012
  Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study.10.1016/j.fct.2012.03.010
• 2012
  Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial.10.1016/j.yrtph.2012.04.003
• 2012
  Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial10.1038/ejcn.2012.126
• 2011
  Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults10.1017/S0007114511004703